Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced unaudited interim and annual consolidated financial results for the fourth quarter and year ended December 31, 2007. The unaudited financial results are subject to further review and potential adjustment as described under the section "Financial Information".

"Throughout 2007, we continued to build our business with the launch of new products, the receipt of regulatory approvals, and the establishment of new partnerships. We expect our new product pipeline and our portfolio of innovative currently marketed products to provide growth and opportunity in 2008 and beyond," said Dr. William Hunter, President and CEO of Angiotech.

"With our expanded sales and marketing team in place and many of our reorganization activities completed, we believe that we are well positioned to achieve our targets for sales growth and gross margin improvements in the coming year," said Tom Bailey, Chief Financial Officer of Angiotech. "We are confident that during 2008 we will begin to realize returns on the various investments we have made in our business over the last two years."

Fourth Quarter Financial Highlights

- Total revenue, as adjusted for non-recurring items, was

$70.7 million. Total revenue under generally accepted accounting

principles (GAAP) was $71.4 million.

- Net product sales, as adjusted, were $43.5 million, and were derived

primarily from sales of our various single use specialty medical

devices as well as from sales of medical device components to third

parties. Net produ 4,927 14,060 9,993 24,053

-------------------------------------------------------------------------

Other income

(expenses):

Foreign exchange

gain (loss) 173 (173)i - (1,263) 1,263 i -

Investment and

other income 511 155 n 666 1,028 4 n 1,032

Interest expense

on long-term debt (12,774) 558 j (12,216) (11,891) 699 j (11,192)

Loss on redemption

of investments - - - 126 (126)l -

Loss on extinguish-

ment of debt - - - (9,297) 9,297 m -

-------------------------------------------------------------------------

(12,090) 540 (11,550) (21,297) 11,137 (10,160)

-------------------------------------------------------------------------

Income (loss) from

continuing

operations before

income taxes and

cumulative effect

of change in

accounting (19,103) 12,480 (6,623) (7,237) 21,130 13,893

Income tax expense

(recovery) (2,275) 3,149 k 874 (1,977) 3,880 k 1,903

-------------------------------------------------------------------------

Net (loss) income

from continuing

operations before

cumulative effect

of change in

accounting (16,828) 9,331 (7,497) (5,260) 17,250 11,990

-------------------------------------------------------------------------

Net loss from

discontinued

operations, net

of income taxes (4,448) 4,448 - (6,443) 6,443 -

-------------------------------------------------------------------------

Net (loss) income

for the period (21,276) 13,779 (7,497) (11,703) 23,693 11,990

-------------------------------------------------------------------------

Basic net (loss)

income per common

share from

continuing

operations (0.20) (0.09) (0.06) 0.14

Diluted net (loss)

income per

common share from

continuing

operations (0.20) (0.09) (0.06) 0.14

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average

shares outstanding

(000's) - basic 85,030 85,030 84,984 84,984

Weighted average

shares outstanding

(000's) - diluted 85,030 85,030 85,547 85,547

-------------------------------------------------------------------------

-------------------------------------------------------------------------

a. One time revenue gain resulting from the up-front monetization of a

royalty revenue stream to be received from our collaboration and

distribution partnership with Orthovita.

b. Amounts accrued for costs incurred, and potential future costs,

related to our offer to accept returns of Contour Threads brand

product as part of consolidation and discontinuation of the Contour

Threads brand name, coincident with the launch of our Quill SRS brand

name.

c. Non-recurring revenue relating to selected licence agreements, net of

licence fees due to licensors.

d. Change in estimate of accounting for excess and obsolete inventory

resulting from the alignment during the fourth quarter of 2007 of

inventory policies across our various manufacturing operations.

e. Stock-based compensation expense.

f. Selling, general and administrative adjustments:

---------------------------------------------------------------------

Three months Three months

ended Dec. 30, ended Dec. 30,

2007 2006

-----------------------------

Stock-based compensation expense (439) (799)

Termination and reorganization costs

related to facility consolidation

and integration activities (3,526) (1,879)

Litigation expenses relating to

defending intellectual property claims 291 (3,551)

---------------------------------------------------------------------

(3,674) (6,229)

---------------------------------------------------------------------

g. Amortization of acquisition related intangible assets and medical

technologies.

h. Non-recurring in-process research and development relating to

payments made to collaborators and licensors, including to

CombinatoRx Inc. and Rex Medical Inc., and a non-recurring license

termination payment of $125,000 to Lipose Corporation made in October

2007.

i. Foreign exchange fluctuations on foreign currency net monetary

assets.

j. Amortization of deferred financing costs.

k. Tax effects of adjustments for the period. Comparative for 2006 also

includes non-recurring retroactive tax adjustment of $8.7 million

relating to certain tax structures previously established in the

province of Quebec, from which the previously expected benefits are

not anticipated to be realized.

l. Loss on redemption of investments.

m. Loss on extinguishment of the term loans related to our December 2006

senior floating rate note refinancing.

n. Includes write off of AMI tax receivable and write off of certain

capitalized costs.

ANGIOTECH PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(in thousands of

U.S.$, except

share and per Year ended Year ended

share data) December 31, 2007 December 31, 2006

-------------------------------------------------------------------------

Adjust- Adjust-

Reported ments Adjusted Reported ments Adjusted

REVENUE

Royalty revenue 116,659 116,659 175,254 (9,000)a 166,254

Product sales, net 170,193 2,579 b 172,772 138,590 138,590

License fees 842 (842)c - 1,231 (1,231)c -

-------------------------------------------------------------------------

287,694 1,737 289,431 315,075 (10,231) 304,844

-------------------------------------------------------------------------

EXPENSES

License and royalty

fees 18,652 18,652 25,409 25,409

Cost of products

sold 95,529 (2,645)d 92,884 68,263 68,263

Research and

development 53,963 (4,582)e 49,381 45,393 (2,490)e 42,903

Selling, general

and administrative 99,713 (16,868)f 82,845 78,732 (17,262)f 61,470

Depreciation and

amortization 33,429 (29,971)g 3,458 36,014 (32,707)g 3,307

In-process research

and development 8,125 (8,125)h - 1,042 (1,042)h -

-------------------------------------------------------------------------

309,411 (62,191) 247,220 254,853 (53,501) 201,352

-------------------------------------------------------------------------

Operating (loss)

income (21,717) 63,928 42,211 60,222 43,270 103,492

-------------------------------------------------------------------------

Other income

(expenses):

Foreign exchange

gain(loss) (341) 341 i - 515 (515)i -

Investment and

other income 10,393 (5,422)j 4,971 6,522 (829)k 5,693

Interest expense on

long-term debt (51,748) 2,242 l (49,506) (35,502) 2,019 l (33,483)

Loss on

sale/write-down

of investments (8,157) 8,157 m - (287) 287 n -

Loss extinguishment

of debt - - - (9,297) 9,297 o -

-------------------------------------------------------------------------

(49,853) 5,318 (44,535) (38,049) 10,259 (27,790)

-------------------------------------------------------------------------

Income (loss) from

continuing

operations before

income taxes and

cumulative effect

of change in

accounting (71,570) 69,246 (2,324) 22,173 53,529 75,702

Income tax expense

(recovery) (23,608) 17,589 p (6,019) 10,279 4,933 p 15,212

-------------------------------------------------------------------------

Income (loss) from

continuing

operations before

cumulative effect

of change in

accounting (47,962) 51,657 3,695 11,894 48,596 60,490

-------------------------------------------------------------------------

Net loss from

discontinued

operations, net

of income taxe (11,395) 11,395 - (7,708) 7,708 -

-------------------------------------------------------------------------

Cumulative effect

of change in

accounting - - - 399 (399) -

-------------------------------------------------------------------------

Net (loss) income

for the period (59,357) 63,052 3,695 4,585 55,905 60,490

-------------------------------------------------------------------------

Basic net (loss)

income per common

share from

continuing

operations (0.56) 0.04 0.14 0.71

Diluted net (loss)

income per common

share from

continuing

operations (0.56) 0.04 0.14 0.71

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average

shares outstanding

(000's) - basic 85,015 85,015 84,752 84,752

Weighted average

shares outstanding

(000's) - diluted 85,015 85,390 85,437 85,437

-------------------------------------------------------------------------

-------------------------------------------------------------------------

a. One time revenue gain resulting from the up-front monetization of a

royalty revenue stream to be received from our collaboration and

distribution partnership with Orthovita.

b. Amounts accrued for costs incurred, and potential future costs,

related to our offer to accept returns of Contour Threads brand

product as part of consolidation and discontinuation of the Contour

Threads brand name, coincident with the launch of our Quill SRS brand

name.

c. Non-recurring, non-operating revenue as derived from license

agreements with Histogenics Corporation ($0.4 million in 2007),

Symphony Medical ($0.2 million in 2007) and other license revenue,

net of license fees due to licensors. In 2006, as derived from

license agreements with Baxter Heathcare Corporation ($1.0 million)

and other license revenue, net of license fees due to licensors.

d. Change in estimate of accounting for excess and obsolete inventory

resulting from the alignment during the third and fourth quarters of

2007 of inventory policies across our various manufacturing

operations, and non-recurring supply / distribution agreement

termination costs.

e. Research and development adjustments:

---------------------------------------------------------------------

Year ended Year ended

Dec. 31, 2007 Dec. 31, 2006

------------------------------

Stock-based compensation (1,665) (2,490)

Non-recurring license fees due to

licensors (419) -

Termination and reorganization costs

related to the integration of AMI (849) -

Non-recurring supply / distribution

agreement termination costs (899) -

Non-recurring in-process research and

development expense relating to the

signing of a technology and intellectual

property license agreement (750) -

---------------------------------------------------------------------

(4,582) (2,490)

---------------------------------------------------------------------

f. Selling, general and administrative adjustments:

---------------------------------------------------------------------

Year ended Year ended

Dec. 31, 2007 Dec. 31, 2006

------------------------------

Stock-based compensation (2,642) (3,609)

Termination and reorganization costs

related to the integration of AMI (8,365) (1,879)

Litigation expenses relating to

defending intellectual property claims (5,611) (11,774)

Non-recurring supply / distribution

agreement termination costs (250) -

---------------------------------------------------------------------

(16,868) (17,262)

---------------------------------------------------------------------

g. Amortization of acquisition related intangible assets and medical

technologies.

h. Non-recurring in-process research and development expense relating to

payments made to licensors and collaborators, including CombinatorX

Inc. and Rex Medical Inc.

i. Foreign exchange fluctuations on foreign currency net monetary

assets.

j. Write off of uncollectible receivable and write off of certain

capitalized costs, net of gain realized on recovery of investments.

k. Gain on sale of Palo Alto building and gain on sale related to

disposition of Neodisc technology rights to NuVasive.

l. Amortization of deferred financing costs.

m. Net impact of loss and gain on redemption of investments of common

share holdings in Orthovita Inc. and NuVasive, Inc., respectively.

n. Net impact of gain on redemption of investments and loss on write

down of investments.

o. Loss on extinguishment of term loans related to our December 2006

senior floating rate note refinancing.

p. Tax effects of adjustments a. through n. for the period, including

the reversal of tax reserves previously booked. Comparative for 2006

also includes non-recurring retroactive tax adjustment of

$8.7 million relating to certain tax structures previously

established in the province of Quebec, from which the previously

expected benefits are not anticipated to be realized.

ANGIOTECH PHARMACEUTICALS, INC.

CALCULATION OF ADJUSTED EBITDA

(Unaudited)

Three months ended Year ended

December 31, December 31,

(in thousands of U.S.$) 2007 2006 2007 2006

-------------------------------------------------------------------------

Net income on a GAAP basis (21,276) (11,703) (59,357) 4,585

Interest expense on long-term debt 12,774 11,891 51,748 35,502

Income tax expense 2,173 (5,619) (23,713) 6,247

Depreciation and amortization 9,902 15,956 37,907 40,348

-------------------------------------------------------------------------

EBITDA 3,573 10,525 6,585 86,682

-------------------------------------------------------------------------

Adjustments:

Net loss from discontinued

operations, excluding

depreciation, amortization and

income tax expense included

above - 9,242 11,122 10,497

In-process research and

development 125 - 8,125 1,042

Non-recurring research and

development costs - - 750 -

Non-recurring revenue, net of

license fees (266) (10,052) (426) (10,231)

Stock-based compensation 589 1,299 4,306 5,700

Litigation expenses (291) 3,551 5,611 11,774

Foreign exchange loss (gain) (173) 1,263 340 (515)

Investment and other income (511) (1,032) (4,814) (5,693)

Severance / restructuring costs 3,526 1,879 8,964 1,879

Supply/distribution agreement

termination costs - - 2,199 -

E&O inventory adjustment 665 - 2,645 -

Loss on extinguishment of debt - 9,297 - 9,297

Contour threads returns - - 2,579 -

Write-off of capitalized costs (401) - 280 -

Write-off of uncollectible tax

receivable - - 2,250 -

Gain on sale of sale of

intangible assets - - - (148)

Gain on sale of Palo Alto building - 4 - (681)

Gain realized on recovery of

investment - - (7,510) -

Accrued interest income - - (597) -

Net loss on redemption of

investments - (126) 8,157 287

-------------------------------------------------------------------------

Adjusted EBITDA 6,836 25,850 50,566 109,890

-------------------------------------------------------------------------

-------------------------------------------------------------------------

ANGIOTECH PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

Dct sales under GAAP were $43.9 million.

- Royalty revenue was $27.2 million, and included $25.4 million of

royalty revenue derived from sales by Boston Scientific Corporation

(BSC) of paclitaxel-eluting coronary stent systems. The average

blended royalty rates indicated during the quarter were 7.5 percent

for U.S. sales, and 5.7 percent for sales recorded in other

countries.

- Adjusted EBITDA (earnings before interest, taxes, depreciation and

amortization, adjusted to exclude certain non-cash and non-recurring

items) was $6.8 million. Excluding research and development expenses,

the significant majority of which are discretionary and relate

primarily to our Pharmaceutical Technologies segment, adjusted EBITDA

would be $20.2 million.

- GAAP net loss and net loss per share from continuing operations were

$16.8 million and $0.20, respectively.

- Adjusted net loss from continuing operations and adjusted net loss

per share from continuing operations (GAAP net loss as adjusted to

exclude certain non-cash and non-recurring items) were $7.5 million

and $0.09, respectively.

- As of December 31, 2007, cash and long-term investments were

$115.8 million and net debt was $465.8 million.

Fourth Quarter Business Highlights

- 5-FU Central Venous Catheter ("CVC"). In December 2007 we submitted a

510(k) application to the U.S. Food and Drug Administration (FDA) to

market and sell our 5-FU CVC. We expect the clinical data from our

recently completed 960 patient clinical trial, which evaluated the

clinical performance of our 5-FU CVC as compared to a market leading

anti-infective CVC, to be presented by the clinical investigators at

the ISICEM 28th International Symposium on Intensive Care and

Emergency Mediciecember 31, December 31,

(in thousands of U.S.$) 2007 2006

-------------------------------------------------------------------------

ASSETS

Cash and short-term investments 91,326 108,617

Accounts receivable 22,678 25,231

Inventories 33,647 33,619

Deferred income taxes 5,964 5,372

Other current assets 7,070 6,303

Assets from discontinued operations - 2,365

-------------------------------------------------------------------------

Total current assets 160,685 181,507

-------------------------------------------------------------------------

Long-term investments 24,456 53,840

Property and equipment, net 59,187 59,783

Intangible assets, net 225,889 244,954

Goodwill 660,591 630,770

Deferred income taxes - 4,804

Deferred financing costs 13,600 14,845

Other assets 6,780 255

Assets from discontinued operations - 15,116

-------------------------------------------------------------------------

Total assets 1,151,188 1,205,874

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities 67,182 67,950

Liabilities from discontinued operations - 4,226

Long-term debt 575,000 575,000

Deferred income taxes 60,386 71,813

Other tax liabilities 2,425 -

Other long-term liabilities 4,614 4,052

Stockholders' equity 441,581 482,833

-------------------------------------------------------------------------

Total liabilities and stockholders' equity 1,151,188 1,205,874

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Forward Looking Statements

--------------------------

Statements contained in this press release that are not based on

historical fact, including without limitation statements containing the

words "believes," "may," "plans," "will," "estimate," "continue,"

"anticipates," "intends," "expects" and similar expressions, constitute

"forward-looking statements" within the meaning of the U.S. Private

Securities Litigation Reform Act of 1995 and constitute "forward-looking

information" within the meaning of applicable Canadian securities laws.

All such statements are made pursuant to the "safe harbor" provisions of

applicable securities legislation. Forward-looking statements may

involve, but are not limited to, comments with respect to our strategies

or future actions, our targets, expectations for our financial condition

and the results of, or outlook for, our operations, research development

and product and drug development. Such forward-looking statements involve

known and unknown risks, uncertainties and other factors that may cause

the actual results, events or developments to be materially different

from any future results, events or developments expressed or implied by

such forward-looking statements. Many such risks, uncertainties and other

factors are taken into account as part of our assumptions underlying

these forward-looking statements and include, among others, the

following: general economic and business conditions, both nationally and

in the regions in which we operate; market demand; technological changes

that could impact our existing products or our ability to develop and

commercialize future products; competition; existing governmental

regulations and changes in, or the failure to comply with, governmental

regulations; adverse results or unexpected delays in drug discovery and

clinical development processes; decisions, and the timing of decisions,

made by health regulatory agencies regarding approval of our technology

and products; the requirement for substantial funding to conduct research

and development and to expand commercialization activities or consummate

acquisitions; sales numbers and future guidance publicly provided by

Boston Scientific Corporation regarding sales of their paclitaxel-eluting

coronary stent products; and any other factors that may affect

performance. In addition, our business is subject to certain operating

risks that may cause the actual results expressed or implied by the

forward-looking statements in this report to differ materially from our

actual results. These operating risks include: our ability to attract and

retain qualified personnel; our ability to successfully complete

preclinical and clinical development of our products; changes in business

strategy or development plans; our failure to obtain patent protection

for discoveries; loss of patent protection resulting from third party

challenges to our patents; commercialization limitations imposed by

patents owned or controlled by third parties; our ability to obtain

rights to technology from licensors; liability for patent claims and

other claims asserted against us; our ability to obtain and enforce

timely patent and other intellectual property protection for our

technology and products; the ability to enter into, and to maintain,

corporate alliances relating to the development and commercialization of

our technology and products; market acceptance of our technology and

products; our ability to successfully manufacture, market and sell our

products; the ability of Boston Scientific Corporation to successfully

manufacture, market and sell their paclitaxel-eluting coronary stent

products; the continued availability of capital to finance our

activities; our ability to achieve the financial benefits expected as a

result of the acquisition of American Medical Instruments Holdings, Inc.

("AMI"); and any other factors referenced in our annual information form

and other filings with the applicable Canadian securities regulatory

authorities or the SEC. Given these uncertainties, assumptions and risk

factors, readers are cautioned not to place undue reliance on such

forward-looking statements. We disclaim any obligation to update any such

factors or to publicly announce the result of any revisions to any of the

forward-looking statements contained in this press release to reflect

future results, events or developments.

Quill(TM) is a trademark of Quill Medical, Inc., a wholly-owned

subsidiary of Angiotech Pharmaceuticals, Inc.

(C)2008 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

Vascular Wrap(TM) is a trademark of Angiotech Pharmaceuticals, Inc.

BioPince(TM) is a trademark of Medical Device Technologies, Inc.

Skater(TM) is a trademark of PBN MEDICALS DENMARK A/S.

MultiStem(R) is a registered trademark of Athersys, Inc.

TAXUS(R) is a registered trademark of Boston Scientific Corporation.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX, ANP) please visit our website at http://www.angiotech.com.

CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, jregts@angio.com; Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056 dneary@angio.com

ne in Brussels, Belgium on March 18, 2008. Should our

5-FU CVC product candidate receive FDA marketing clearance, we would

anticipate commencing commercial launch activities in the second half

of 2008.

- Quill(TM) SRS: In October 2007 we received CE Mark approval to begin

marketing the Quill(TM) Self-Retaining System (SRS) MONODERM(TM)

product line in Europe. In addition, we exceeded our stated goal of

100 Quill(TM) SRS hospital accounts by the end of 2007, and expect to

expand the number of Quill(TM) SRS SKUs available for sale to our

customers in 2008.

- Vascular Wrap(TM): Enrolment in our AV access human clinical trials

in the U.S. and Europe continues and we currently expect to complete

enrolment in these studies around the end of the first half of 2008.

- Stem Cell Therapies: In December 2007 our partner, Athersys, Inc.

received authorization from the U.S. FDA to begin a Phase I clinical

trial evaluating the safety of MultiStem(R) in the treatment of acute

myocardial infarction. We have an agreement with Athersys to co-

develop and commercialize MultiStem(R), Athersys' non-embryonic stem

cell platform technology, for use in the indications of acute

myocardial infarction and peripheral vascular disease.

- TAXUS(R) paclitaxel-eluting stent systems: In December 2007 our

partner, BSC, announced that the TAXUS(R) Liberte(TM) paclitaxel-

eluting coronary stent system received European CE Mark approval for

use in diabetic patients.

2008 Outlook

Our financial outlook for the upcoming fiscal year ending December 31, 2008 is presented below. Several material factors and assumptions were used to derive our 2008 outlook, including: (i) estimates of medical procedure and patient population growth rates for the various end markets relating to our medical products business; (ii) estimates of the impact of pricing changes, pricing strategies and competition with respect to certain of our currently marketed medical products; (iii) competitive analysis and estimates of relative market share with respect to certain key product lines; (iv) estimates of revenue growth and customer composition relating to our sales of medical device components to other medical products companies; (v) analysis of the impact of our manufacturing consolidation, product sales mix and pricing on cost of goods sold; (vi) estimates of selling, general and administrative expenses necessary to support our revenue growth and overall business goals; and (vii) estimates of research and clinical expenses necessary to support our various new product development and research programs.

The outlook presented below contains estimates of certain expenses based on non-GAAP measures, and are prepared consistent with our current and previous presentations of our historical financial information. Specifically, our outlook for research and clinical expenses, sales and marketing expenses and general and administrative expenses exclude estimates for stock based compensation expenses, for certain non-recurring expenses expected to be incurred in the first half of 2008 related to the completion of the consolidation of our Syracuse, NY operations, and for certain litigation related expenses. The estimates for these certain operating expenses are inherently unpredictable or subject to significant fluctuation for reasons unrelated to our business performance.

The key elements of our 2008 outlook are as follows:

- Medical Products year over year total revenue growth goal of 15% or

greater, with higher growth expected from several selected promoted

brand product lines, including Quill(TM) SRS, Skater(TM) drainage

catheters, EnSnare(R) vascular retrieval devices, and our

BioPince(TM) biopsy needle franchise, among others;

- Improvements in gross margins as compared to 2007, driven by a

combination of expected improvements in product sales mix and the

expected completion of the consolidation and closure of our

operations in Syracuse, New York;

- Research and clinical expenses ranging from $45 to $50 million, with

expenses weighted to the first half of 2008, driven primarily by

continued clinical, manufacturing and pre-launch activities related

to our 5-FU CVC and Vascular Wrap(TM) product candidates;

- Sales and marketing expenses ranging from $50 to $60 million, driven

by the achievement of stated sales goals and the incurrence of a full

year of certain expenses related to the 2007 expansion of our sales

and marketing personnel;

- General and administrative expenses ranging from $40 to $45 million,

reflecting continued reductions in selected administrative expenses

as compared to 2007; and

- Capital expenditures ranging from $12 to $15 million.

Our financial outlook is forward-looking information, and actual results may be materially different from any results, events or developments expressed or implied by our financial outlook. We expect our financial results may vary from the outlook provided as a result of several key factors, including the progress of our various research, clinical development and product launch initiatives, the achievement of selected sales growth targets and the timing of product sales growth, the outcome of various ongoing partnering, business development and financing discussions, and the level of royalty revenues we receive from our partner BSC in future periods and the impact such results may have on our election to pursue certain discretionary aspects of our budgeted expenses in 2008. It is expected that, at the present time, we will have adequate cash and liquidity resources to execute our various research, product development and growth initiatives in 2008.

Our financial outlook is provided to give investors an assessment of our expected financial results and our future business, and may not be appropriate for any other purposes. Given the risks, uncertainties and assumptions associated with such information, readers are cautioned not to place undue reliance on our financial outlook. Except as required by law, we disclaim any obligation to update our financial outlook.

Financial Information

---------------------

This press release contains the condensed financial information derived from the preliminary unaudited interim consolidated financial statements for the three month periods ended December 31, 2007 and 2006, and preliminary unaudited consolidated financial statements for the years ended December 31, 2007 and 2006 as previously reported. The unaudited financial information presented should be considered preliminary and is subject to potential adjustments, including, but not limited to, potential adjustments to certain tax related items, pending the conclusion of the 2007 year-end audit. Upon completion of the 2007 year-end audit process and the approval of our full year 2007 audited consolidated financial statements by our Board of Directors, full audited consolidated financial statements and Management's Discussion and Analysis for the three years ended December 31, 2007, will be filed with the relevant regulatory agencies, as well as posted on our website at http://www.angiotech.com.

We completed the acquisition of the operations of American Medical Instruments Holdings, Inc. ("AMI") on March 23, 2006. Because of the timing of the AMI acquisition, our operating results for the twelve month period ended December 31, 2006 include AMI's results of operations from the period of March 24, 2006 to December 30, 2006, as compared to the current twelve month period which reflects combined results for the full year. As a result, our results for the twelve months ended December 31, 2007 do not reflect a comparable operating period as compared to the nine months ended December 31, 2006.

Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported under GAAP unless otherwise noted. All per share amounts are stated on a diluted basis unless otherwise noted.

Use of Certain Non GAAP Financial Measures

------------------------------------------

Certain financial results presented in this press release include non-GAAP measures that exclude certain items. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations and adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA") exclude certain non-cash and non-recurring items such as acquisition related amortization charges, acquired in-process research and development relating to license agreements and acquisitions, stock-based compensation expense, foreign exchange gains or losses relating to translation of foreign currency cash and investment balances and other non-recurring items. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations and adjusted EBITDA also exclude litigation expenses related to defending intellectual property claims. Revenue, as adjusted, excludes non-recurring, non-operating revenue derived from license agreements and other license revenue, net of license fees due to licensors and excludes amounts accrued for costs incurred, and potential future costs, related to our offer to accept returns of Contour Threads brand product as part of our announced brand name consolidation and discontinuation. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations, revenue, as adjusted, and adjusted EBITDA do not have any standardized meaning prescribed by GAAP and therefore may not be comparable to similar measures presented by other issuers. Management uses these non-GAAP or adjusted operating measures to establish operational goals, and believes that these measures may assist investors in analyzing the underlying trends in our business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, financial reporting measures prepared in accordance with GAAP. We have provided a reconciliation of these measures to GAAP in the attached tables.

The financial outlook referred to above presents certain forward-looking, non-GAAP financial information for which at this time there is no calculable comparable GAAP measure. As a result, such non-GAAP financial information cannot be quantitatively reconciled to comparable GAAP financial information. Specifically, the estimates for certain operating expenses referred to above exclude estimates of certain expenses that are inherently unpredictable or subject to significant fluctuation for reasons unrelated to our business performance, including stock-based compensation expenses, certain litigation expenses and foreign exchange gains or losses.

Conference Call Information

---------------------------

A conference call to discuss these financial results will be held today, Thursday, February 14, 2008 at 8:00 AM PT (11:00 AM ET).

Dial-in information:

North America (toll free): (866) 510-0711

International: (617) 597-5379

Enter passcode: 91184096

A replay archive of the conference call will be available until February 21, 2008 by calling (888) 286-8010 (in North America) or (617) 801-6888 (International) and entering Access Code 85112963.

A live webcast will be available to all interested parties through the Investors section of Angiotech's website: http://www.angiotech.com.

ANGIOTECH PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(in thousands of

U.S.$, except

share and per Three months ended Three months ended

share data) December 31, 2007 December 31, 2006

-------------------------------------------------------------------------

Adjust- Adjust-

Reported ments Adjusted Reported ments Adjusted

REVENUE

Royalty revenue 27,158 27,158 47,475 (9,000)a 38,475

Product sales, net 43,935 (401)b 43,534 44,726 44,726

License fees 266 (266)c - 1,052 (1,052)c -

-------------------------------------------------------------------------

71,359 (667) 70,692 93,253 (10,052) 83,201

-------------------------------------------------------------------------

EXPENSES

License and royalty

fees 4,527 4,527 6,048 6,048

Cost of products

sold 24,158 (665)d 23,493 22,465 22,465

Research and

development 13,556 (150)e 13,406 12,165 (500)e 11,665

Selling, general

and administrative 27,180 (3,674)f 23,506 24,227 (6,229)f 17,998

Depreciation and

amortization 8,826 (7,993)g 833 14,288 (13,316)g 972

In-process research

and development 125 (125)h -

-------------------------------------------------------------------------

78,372 (12,607) 65,765 79,193 (20,045) 59,148

-------------------------------------------------------------------------

Operating (loss)

income (7,013) 11,940
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):